#1 Clinical Trials Search in Europe

Olaparib

Olaparib, also known by its brand name Lynparza, is a promising drug being studied in various clinical trials for the treatment of different types of cancer. This article summarizes key information about ongoing clinical trials investigating the use of olaparib in conditions like ovarian, breast, prostate, and pancreatic cancers. We’ll explore how this PARP inhibitor is being evaluated for its efficacy, safety, and potential to improve outcomes for cancer patients.

Table of Contents

What is Olaparib?

Olaparib, also known by its brand name Lynparza, is a medication used in the treatment of certain types of cancer[1]. It belongs to a class of drugs called PARP inhibitors, which work by blocking an enzyme in cells called PARP (Poly ADP-ribose polymerase)[1]. Olaparib is primarily used to treat ovarian cancer, but research is ongoing to explore its effectiveness in other types of cancer as well.

How Olaparib Works

Olaparib works by targeting a specific weakness in some cancer cells. In normal cells, there are multiple ways to repair damaged DNA. However, some cancer cells, particularly those with mutations in genes like BRCA1 or BRCA2, rely heavily on the PARP enzyme for DNA repair[1]. By blocking PARP, Olaparib makes it difficult for these cancer cells to repair their DNA, which can lead to their death. This targeted approach allows Olaparib to be effective against cancer cells while potentially causing less harm to normal cells.

Conditions Treated with Olaparib

Olaparib is approved for use in several types of cancer, including:

  • Ovarian Cancer: Olaparib is used to treat advanced ovarian cancer, particularly in patients with BRCA mutations[2]. It’s often used as a maintenance therapy after chemotherapy to help keep the cancer from coming back.
  • Breast Cancer: Some studies are exploring the use of Olaparib in metastatic breast cancer patients with BRCA mutations[1].
  • Pancreatic Cancer: Research is being conducted on the use of Olaparib in pancreatic cancer patients with BRCA mutations[3].
  • Prostate Cancer: Some trials are investigating Olaparib’s effectiveness in prostate cancer[1].

How Olaparib is Administered

Olaparib is typically taken orally in the form of tablets or capsules. The usual dose is 300 mg taken twice daily, although this can vary depending on the specific condition being treated and the patient’s response to the medication[2]. It’s important to take Olaparib exactly as prescribed by your doctor. The treatment usually continues until the cancer progresses or unacceptable side effects occur.

Effectiveness of Olaparib

Clinical trials have shown promising results for Olaparib in several types of cancer:

  • Ovarian Cancer: In patients with platinum-sensitive relapsed ovarian cancer and BRCA mutations, Olaparib has been shown to significantly improve progression-free survival compared to placebo[2].
  • Breast Cancer: Studies in metastatic breast cancer patients with BRCA mutations have shown encouraging response rates to Olaparib[1].
  • Pancreatic Cancer: Early research suggests that Olaparib may be effective in some pancreatic cancer patients with BRCA mutations[3].

Side Effects and Safety

Like all medications, Olaparib can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Fatigue
  • Anemia (low red blood cell count)
  • Diarrhea
  • Decreased appetite

More serious side effects, although less common, can include bone marrow problems leading to low blood cell counts, and rarely, the development of other cancers[2]. It’s important to discuss all potential side effects with your doctor and report any new or worsening symptoms during treatment.

Ongoing Research

Research on Olaparib is ongoing, with several clinical trials exploring its use in different types of cancer and in combination with other treatments. Some areas of current research include:

  • Use of Olaparib in newly diagnosed ovarian cancer patients[4]
  • Combination of Olaparib with other cancer treatments[5]
  • Effectiveness of Olaparib in patients with different types of genetic mutations[6]
  • Impact of factors like diabetes on Olaparib’s effectiveness[7]

These ongoing studies aim to further understand how Olaparib can be used most effectively to help cancer patients.

Aspect Details
Drug Name Olaparib (also known as Lynparza, AZD2281, KU-0059436)
Drug Class PARP (poly ADP-ribose polymerase) inhibitor
Cancer Types Studied Ovarian, breast, prostate, pancreatic, renal cell carcinoma
Common Dosages 300mg to 600mg daily, often divided into two doses
Administration Oral tablets
Key Outcome Measures Progression-free survival, overall survival, objective response rate, duration of response, safety/tolerability
Genetic Factors Often focused on BRCA1/2 mutations and other DNA repair gene mutations
Combination Therapies Some trials exploring combination with other drugs (e.g., elacestrant in breast cancer)
Patient Populations Often advanced or metastatic cancers, sometimes after prior treatments have failed

FAQ

  • What is olaparib and how does it work? Olaparib is a PARP (poly ADP-ribose polymerase) inhibitor. It works by blocking enzymes that help repair damaged DNA in cancer cells, potentially stopping the growth of tumor cells.
  • What types of cancer is olaparib being studied for? Based on the clinical trials data, olaparib is being investigated for various cancers including ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma.
  • How is olaparib administered in these trials? In most trials, olaparib is given orally in tablet form. The dosage varies, but common doses are 300mg or 600mg daily, often divided into two doses taken 12 hours apart.
  • What are some of the main outcomes being measured in olaparib trials? Key outcomes include progression-free survival, overall survival, objective response rate, duration of response, and safety/tolerability of the drug. Some trials also look at quality of life measures.
  • Are there any specific genetic factors that may influence olaparib's effectiveness? Yes, several trials focus on patients with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Some studies also look at other DNA repair gene mutations that might make cancers more responsive to PARP inhibitors like olaparib.

Ongoing Clinical Trials on Olaparib

  • Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Poland Spain

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Iceland +6

  • Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Metastatic Squamous Non-small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria France Germany Poland Romania Spain

  • Study on the Effectiveness of Carboplatin and Olaparib for Patients with Triple-Negative Breast Cancer with Positive HRD Status

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria France Germany Poland Romania Spain

  • Study of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Finland Germany Spain

  • Study on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Pembrolizumab and Olaparib for Patients with Advanced Colorectal Cancer with DNA Repair Deficiency

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Czechia Estonia France Germany Hungary Italy +6

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Estonia France Greece Hungary +5

Glossary

  • PARP inhibitor: A type of drug that blocks an enzyme called poly (ADP-ribose) polymerase. PARP inhibitors may help keep cancer cells from repairing their damaged DNA, causing them to die.
  • BRCA1/BRCA2: Genes that produce proteins helping to repair damaged DNA. When these genes are mutated, they increase the risk of certain cancers, particularly breast and ovarian cancers.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment based on whether tumors shrink, stay the same, or get bigger.
  • Ctrough: The lowest concentration of a drug in the blood, typically just before the next dose is administered.
  • Homologous recombination deficiency (HRD): A type of genetic abnormality that affects how cells repair damaged DNA, potentially making cancers more sensitive to certain treatments like PARP inhibitors.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Castration-resistant prostate cancer: Prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels.

References

  1. https://clinicaltrials.gov/study/NCT03344965
  2. https://clinicaltrials.gov/study/NCT02282020
  3. https://clinicaltrials.gov/study/NCT02511223
  4. https://clinicaltrials.eu/trial/study-on-olaparib-for-maintenance-therapy-in-patients-with-newly-diagnosed-advanced-ovarian-fallopian-tube-and-peritoneal-cancer/
  5. https://clinicaltrials.gov/study/NCT04410887
  6. https://clinicaltrials.gov/study/NCT02983799
  7. https://clinicaltrials.gov/study/NCT05081765